# Zynex Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Zynex Inc). ## Overview Zynex Inc. is a U.S.-based medical device company headquartered in Englewood, Colorado, focused on electrotherapy and pain management products. Through its operating subsidiaries, it sells and leases devices and supplies used in home and clinical settings, and it also owns a patient-monitoring technology platform developed through its ZMS subsidiary. ## Products & services • Electrotherapy devices for pain management • Consumable supplies such as electrodes and batteries • Device sales and rentals • Private-labeled rehabilitation products • Laser-based patient monitoring technologies • Multi-parameter pulse oximetry and hemoglobin monitoring - **Electrotherapy devices** (45%) — Pain-management and rehabilitation devices sold or leased to patients and providers. - **Supplies** (45%) — Recurring consumables used with electrotherapy products, mainly electrodes and batteries. - **Private-labeled rehabilitation products** (5%) — Branded support and therapy products sold alongside the core device portfolio. - **Patient monitoring technologies** (5%) — Laser-based noninvasive monitoring products under development through ZMS/Kestrel. - Electrotherapy devices for pain management - Consumable supplies such as electrodes and batteries - Device sales and rentals - Private-labeled rehabilitation products - Laser-based patient monitoring technologies - Multi-parameter pulse oximetry and hemoglobin monitoring ## Customers Zynex sells primarily into the U.S. healthcare market, with reimbursement-driven demand from patients using electrotherapy products and the providers or payers that support those prescriptions. Its products are used for pain management, rehabilitation, and patient monitoring, so customer demand depends on clinical adoption, insurance reimbursement, and durable repeat supply usage. - **Home-use pain management patients** (primary) — Patients who receive electrotherapy devices and recurring supplies for chronic pain or rehabilitation. - **Healthcare payers and insurers** (primary) — Third-party payers that determine reimbursement levels and claim acceptance for device and supply revenue. - **Physicians and prescribing clinics** (secondary) — Clinicians that drive patient placement by recommending Zynex devices and related supplies. - **Strategic commercialization partners** (emerging) — Potential partners for NiCO and HemeOx who could help bring monitoring technologies to market. - Patients using prescribed electrotherapy devices at home - Healthcare payers and insurers that reimburse claims - Physicians and clinics that prescribe or recommend devices - Patients needing recurring electrodes and batteries - Potential strategic partners for monitoring technologies ## Geography Zynex is headquartered in Englewood, Colorado and conducts most of its operations through U.S.-based subsidiaries. The business is primarily exposed to the United States healthcare reimbursement system, while its monitoring technology efforts also create exposure to regulatory and commercialization pathways outside the core device business. - Headquartered in Englewood, Colorado - Most operations run through U.S. subsidiaries ZMI and ZMS - Core revenue is tied to the U.S. healthcare reimbursement system - Inactive subsidiaries include Zynex Europe and other legacy entities - Trade policy and import exposure can affect sourced components ## Strategy Zynex’s core strategy centers on selling and supporting electrotherapy devices and recurring supplies through its U.S. commercial platform. It is also seeking to advance or monetize its noninvasive monitoring technologies through strategic partnerships rather than independent commercialization, which changes how the company may develop and fund that pipeline. - **Grow core electrotherapy and supply franchise** (short-term) — Recurring supplies and device placements are the main commercial engine of the business. - **Increase sales force productivity** (short-term) — The company depends on efficient patient acquisition and prescription conversion. - **Partnerize monitoring technologies** (medium-term) — Strategic partners may provide regulatory, commercial, and funding support for NiCO and HemeOx. - Expand electrotherapy and supply penetration in the U.S. - Improve sales force productivity and order quality - Use recurring supplies to support customer lifetime value - Pursue strategic partners for NiCO and HemeOx - Preserve optionality across device and monitoring platforms ## Risks Zynex is exposed to reimbursement, payer, and claim-processing risk because a large part of its revenue depends on third-party payment decisions and patient collections. It also faces development, regulatory, and partnership risk in its monitoring technologies, plus supply-chain and tariff exposure for components sourced outside the U.S. - **Third-party payer reimbursement disruption** [high] — Revenue depends on insurer payment decisions, claim processing, and patient eligibility. - **Strategic partnership execution risk** [high] — NiCO and HemeOx may require external partners to reach market and generate value. - **Tariffs and import cost inflation** [medium] — Manufactured products and components sourced outside the U.S. may become more expensive. - **Regulatory and litigation risk** [medium] — SEC requests and other legal matters can create expense, uncertainty, and reputational damage. - Third-party payer suspensions can disrupt device and supply revenue - Reimbursement deductions and refund requests affect collectability - Monitoring technologies may not secure partners or approvals - Tariffs can raise component costs and pressure margins - Litigation and SEC inquiry can distract management and add cost ## Accounting Zynex recognizes device and supply revenue net of estimated third-party payer reimbursement deductions and allowance for uncollectible accounts, which makes revenue sensitive to claim outcomes and collection estimates. Goodwill and intangible assets tied to Kestrel/ZMS are also important because impairment testing can materially affect reported results when commercialization plans change or asset values decline. - **Revenue recognition net of payer deductions** — Can materially change net revenue and receivables - **Allowance for uncollectible accounts** — Affects revenue, accounts receivable, and cash conversion - **Goodwill and intangible impairment** — Can create large non-cash charges - **Income tax valuation allowance and discrete items** — Affects effective tax rate and net income - Net revenue is reduced by estimated payer reimbursement deductions - Allowance estimates affect reported revenue and receivables - Refund requests and claim denials require judgmental reserves - Goodwill and intangibles are exposed to impairment testing - Quarterly tax expense can swing with discrete items and valuation allowances --- *Last updated: 2026-04-29T05:11:33.774477+00:00*